课题基金 / 基金详情

Transdermal Cannabidiol Prodrug Delivery

Transdermal Cannabidiol Prodrug Delivery
透皮大麻二酚前药递送
批准号:
8199298
负责人:
Audra L. Stinchcomb
金额:
$16.05万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2011
资助国家:
美国
项目状态:
已结题
起止时间:
2011-07-15 至 2011-12-31

项目摘要

项目成果

Audra L. Stinchcomb的其他基金

相似基金

相关文献

中文摘要
翻译
描述(由申请人提供):超过8.5%的美国人口和全球7500万人符合酒精使用障碍(AUD)的诊断标准,酒精滥用是美国和世界上三大可预防的公共卫生问题之一。AUD,通常被称为酒精中毒,具有复杂的病因学,其中慢性酒精相关的神经变性,戒断相关的焦虑和持续的酒精渴望是高复发率和不良临床结局的预测。AUD的治疗将受益于可以解决这些被忽视的终点以改善临床结局的药理学方法。然而,在目前FDA批准用于治疗过度饮酒的三种药物中,没有一种可以解决神经退行性疾病,戒断或焦虑。大麻二酚(CBD)是一种可以改善这三种综合征的药物。 大麻素的经皮给药是口服给药的可行替代方案。大多数大麻素在肝脏中高度代谢。CBD的口服生物利用度仅约为6%,并且在CBD口服剂量临床试验中检测到非常低的血浆药物水平。由于药物剂型的选择不佳,患者口服剂量大麻素的临床试验极有可能得出不一致的结果。我们假设可以开发CBD透皮剂型,并且这种剂型可以在未来的酒精患者临床研究中提供治疗水平的药物。整个项目的长期假设是,CBD将减少戒断相关的焦虑和控制酒精渴望,从而通过调节内源性大麻素系统降低酗酒者的高复发易感性。在实现这一目标的第一步中,将对通过透皮微针递送的CBD前药进行概念验证评估。CBD本身不会以治疗速率渗透皮肤,除非它作为凝胶应用于大的皮肤表面积,因为经皮应用的面积与递送速率成正比。前药是化学修饰的母体药物,其比母体药物更具有皮肤渗透性,并且一旦它们穿过角质层就迅速分离回母体药物和前药部分。AllTranz的初步数据显示,单独的CBD前药不会改善皮肤渗透,除非前药是专门设计用于微针。此外,与用于微针递送的优化的CBD前药相比,单独使用微针的CBD递送没有显著增强。具体来说,我们的目标是合成CBD的前药,其与微针装置组合将是非常皮肤可渗透的。然后,我们的目标是评估其在体外人体皮肤渗透的最佳流量。在未来的研究中,我们将开发原型产品并申请IND,并开始在健康对照组和酗酒者中进行I期临床试验。未来的CBD透皮系统也可以在II期临床试验中测试阿片成瘾,镇痛作用,炎症缓解(关节炎)以及恶心和呕吐治疗,因为CBD有大量的临床前/临床数据来证明这些适应症的治疗效用。 公共卫生相关性: 超过8.5%的美国人口和全球7500万人符合酒精使用障碍(AUD)的诊断标准,酒精滥用是美国和世界上三大可预防的公共卫生问题之一。目前批准的治疗酒精中毒和其他类型药物成瘾的药物治疗是有限的,因为它们不能解决成瘾的多个方面:渴望,神经变性,戒断和焦虑。拟议的临床前研究将加速大麻二酚(CBD)在适当的递送系统中的测试,以评估其作为寻找新型酒精中毒和其他药物成瘾药物疗法的主要候选者的潜在益处。未来的CBD透皮系统也可以在II期临床试验中测试镇痛效果,炎症缓解以及恶心和呕吐治疗,因为CBD也有大量的临床前/临床数据来证明这些适应症的治疗效用。
英文摘要
DESCRIPTION (provided by applicant): With over 8.5% of the U.S. population and 75 million people worldwide meeting the diagnostic criteria for alcohol use disorders (AUDs), alcohol abuse is among the top three preventable public health problems in the U.S. and the world. AUDs, commonly referred to as alcoholism, have a complex etiology where chronic alcohol associated neurodegeneration, withdrawal-related anxiety and persistent alcohol craving are predictive of high relapse and poor clinical outcomes. The treatment of AUDs would benefit from a pharmacological approach that could address these overlooked endpoints to improve clinical outcomes. However, of the three drugs currently FDA-approved for the treatment of excessive alcohol consumption, none address neurodegeneration, withdrawal or anxiety. Cannabidiol (CBD) is a drug that could improve these three syndromes. Transdermal drug delivery of cannabinoids is a viable alternative to oral dosing. Most of the cannabinoids are highly metabolized in the liver. The oral bioavailability of CBD is only about 6%, and very low plasma drug levels were detected in CBD oral dose clinical trials. It is highly possible that clinical trials of oral dose cannabinoids in patients have given inconsistent results because of a poor choice of drug dosage form. We hypothesize that a CBD transdermal dosage form can be developed, and that this dosage form could provide therapeutic levels of drug in a future clinical study with alcoholic patients. The long-term hypothesis of the overall project is that CBD will decrease withdrawal related anxiety and control alcohol craving, thereby decreasing high relapse susceptibility in alcoholics by modulating the endocannabinoid system. In the first step towards this goal, a proof of concept evaluation of CBD prodrugs delivered via transdermal microneedles will be conducted. CBD itself does not permeate the skin at a therapeutic rate, unless it is applied as a gel to a large skin surface area, as the area of transdermal application is directly proportional to the delivery rate. Prodrugs are chemically modified parent drugs that are more skin permeable than the parent, and once they cross the stratum corneum quickly separate back into the parent drug and prodrug moiety. AllTranz has preliminary data showing that CBD prodrugs alone do not improve skin permeation, unless the prodrugs are specifically designed for use with microneedles. Additionally, CBD delivery with microneedles alone is not significantly enhanced, as compared to optimized CBD prodrugs for microneedle delivery. Specifically we aim to synthesize prodrugs of CBD that will be very skin permeable in combination with a microneedle device. We then aim to assess their in vitro human skin permeation for optimum flux. In future studies we will develop the prototype product and apply for an IND and begin Phase I clinical trials in healthy controls and alcoholics. The future CBD transdermal system could also be tested in Phase II clinical trials for opiate addiction, analgesic effect, inflammation relief (arthritis), and nausea and vomiting treatment, as there is substantial preclinical/clinical data with CBD to justify therapeutic utility for these indications. PUBLIC HEALTH RELEVANCE: With over 8.5% of the U.S. population and 75 million people worldwide meeting the diagnostic criteria for alcohol use disorders (AUDs), alcohol abuse is among the top three preventable public health problems in the U.S. and the world. Currently approved pharmacological treatments in the treatment of alcoholism and other types of drug addiction are limited in that they do not address multiple aspects of addiction: craving, neurodegeneration, withdrawal and anxiety. The proposed preclinical research will accelerate testing of cannabidiol (CBD) in an appropriate delivery system to assess its potential benefits as a lead candidate in the search for novel alcoholism and other drug addiction pharmacotherapies. The future CBD transdermal system could also be tested in Phase II clinical trials for analgesic effect, inflammation relief, and nausea and vomiting treatment, as there is also substantial preclinical/clinical data with CBD to justify therapeutic utility for these indications.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Heat Effect on Generic Transdermal Drug Delivery Systems
  • 批准号:
    9340991
  • 项目类别:
  • 资助金额:
    $50.0万
  • 财政年份:
    2013
  • 负责人:
    Audra L. Stinchcomb
  • 依托单位:
Transdermal Naltrexone for Opiate Addiction and Alcoholism
  • 批准号:
    8253142
  • 项目类别:
  • 资助金额:
    $53.78万
  • 财政年份:
    2012
  • 负责人:
    Audra L. Stinchcomb
  • 依托单位:
Microneedle-enhanced codrug delivery for smoking cessation and appetite suppressi
  • 批准号:
    8508902
  • 项目类别:
  • 资助金额:
    $23.01万
  • 财政年份:
    2012
  • 负责人:
    Audra L. Stinchcomb
  • 依托单位:
Transdermal Naltrexone for Opiate Addiction and Alcoholism
  • 批准号:
    8519709
  • 项目类别:
  • 资助金额:
    $69.6万
  • 财政年份:
    2012
  • 负责人:
    Audra L. Stinchcomb
  • 依托单位:
海外基金